2​ Biological Activity WAY-600 is a potent ATP-competitive mTOR inhibitor with an IC50 of about 9 nM. It is well reported that the mammalian target of rapamycin (mTOR) is centrally involved in cell growth, metabolism, and angiogenesis. WAY-600 has significant selectivity against mTOR over phosphatidylinositol 3-kinase (PI3K) isofoms (>100-fold). WAY-600 treated HEK293 cells indicated a 50% inhibition of polysomes by way-600 compared with the 11% suppression by rapamycin. Unlike the rapalogs,WAY-600 acutely blocked mTORC2-dependent phosphorylation of AKT in vitro and in vivo. In various cancer cells,WAY-600 inhibited the mTORC1 substrate P-S6K(T389) and mTORC2 substrate P-AKT(S473) at submicromolar concentrations without significant inhibition of P-AKT(T308). [1][2] 3​ References: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin Yu K et al. Cancer Res 2009 Aug 1;69(15):6232-40 mTOR Mediated Anti-Cancer Drug Discovery. Liu Q et al. Drug Discov Today Ther Strateg 2009;6(2):47-55 The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.